華蘭生物(002007.SZ):部分高管擬實施下一期減持計劃 擬減持139.1萬股
格隆匯4月12日丨華蘭生物(002007.SZ)公佈,近日,公司收到公司高級管理人員範蓓、王啟平、潘若文、張寶獻、馬小偉、謝軍民和安文琪出具的《告知函》,截至2020年4月11日,前次減持計劃期限已屆滿,並擬實施下一期減持計劃。
首期股份減持計劃的實施情況:彼等已合計減持70.0052萬股,佔公司總股本的比例0.0499%。
擬實施下一期減持計劃:彼等擬減持股份數量139.1萬股,佔公司總股本的比例0.0991%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.